HIV-1 transmission in utero accounts for 20-30% of vertical transmission events in breast-feeding populations. In a prospective study of 463 HIV-1infected mothers and infants, illness during pregnancy was associated with 2.6-fold increased risk of in-utero HIV-1 transmission [95% confidence interval (CI) 1.2-5.8] and bacterial vaginosis with a three-fold increase (95% CI 1.0-7.0) after adjusting for maternal HIV-1 viral load. Interventions targeting these novel risk factors could lead to more effective prevention of transmission during pregnancy. c Includes fever lasting > 1 month, diarrhea lasting >1 month, cough lasting >1 month, weight loss >5 kg, dermatitis, and thrush.
In developing countries, most effective prevention of mother-to-child HIV-1 transmission interventions target intrapartum and breast-milk transmission. These include single dose nevirapine at delivery, short-course antiretrovirals, highly active antiretroviral therapy during breast feeding, breast-milk avoidance, early weaning from breast milk, and infant nevirapine prophylaxis [1] [2] [3] . As these interventions become more widely available, in-utero transmission is likely to contribute to an increased proportion of mother-to-child transmission events. Determining factors associated with HIV-1 transmission in utero is an important step toward adapting interventions designed to further prevent infant HIV-1 infection.
A number of maternal, infant, and viral factors have been studied in association with in-utero transmission. Those with the strongest evidence for an association include maternal HIV-1 viral load, antenatal antiretroviral therapy, infant sex, low birthweight, and ascending infections, such as chorioamnionitis [4] . The goal of the current study was to define additional correlates of inutero transmission within a prospective cohort of HIV-1infected Kenyan women and infants.
HIV-1-infected pregnant women were followed biweekly during pregnancy and at 34-36 weeks of pregnancy began oral zidovudine, which they continued through delivery. Sexually transmitted infections (syphilis, gonorrhea, chlamydia, trichomoniasis) and candida were treated following Kenya National Guidelines. After study completion, slides were evaluated for bacterial vaginosis using Nugent's criteria and blood collected at 32 weeks of gestation was assayed for HIV-1 RNA viral load. Neonatal blood collected at birth was tested for HIV-1 DNA on filter paper specimens and HIV-1 RNA in plasma using PCR [5] . In-utero transmission was defined as a positive DNA or RNA assay at less than 48 h after birth. Mother-infant pairs were subsequently followed up monthly, with infant HIV-1 PCR assays performed every 3 months until 12 months postpartum.
Between 1999 and 2002, 36 000 pregnant women were screened for HIV-1, of whom 31 731 (88%) accepted testing and 4512 (14%) were HIV-1-seropositive. Onethird of these women accepted referral to the study clinic and 463 (30%) among these consented to study participation and were followed up through delivery. Of the 463, 88 (19%) women had infants who were infected with HIV-1, 77 (17%) infants died, and 48 (10%) were lost to follow-up. Twenty-nine (33%) infants among the 88 infected infants were HIV-1 PCR positive within 48 h of birth and considered infected in utero. Thirty-seven (42%) infants were HIV-1-uninfected at birth and infected at month 1, thus infected intrapartum or via early breastmilk exposure, and 10 (11%) infants were infected via breast milk after 1 month of age. Twelve (14%) infants did not have specimens at birth and precise timing of infection could not be determined; these infants may have been infected in utero, intrapartum, or early postpartum and were excluded from analyses.
Twenty-nine infants infected in utero were compared with 422 infants who were either infected at other time points or remained HIV-1-uninfected during the 12-month study period. Plasma and cervical HIV-1 viral load were found to be approximately one-half log 10 higher for women who transmitted in utero than those who did not (plasma: 5.0 vs. 4.6 log copies/ml; P < 0.001 and cervical: 3.0 vs. 2.4; P ¼ 0.004). Whereas absolute CD4 cell count was not different for women in the two groups, CD4 percentage was lower for transmitting women (19.8 vs. 23.6%; P ¼ 0.01). Women who transmitted were also significantly less likely to have received at least 3 weeks of zidovudine (P ¼ 0.02) and 57% of transmitting women had not completed a 3-week course of antiretrovirals prior to delivery. There was a trend for more female infants to acquire HIV-1 in utero (66 vs. 47%; P ¼ 0.06) and infants infected in utero had significantly lower birthweight (2.9 vs. 3.1 kg; P < 0.001) and gestational age using modified Dubowitz criteria (38.5 vs. 39.3 weeks gestation; P ¼ 0.02).
Antenatal diagnosis of a sexually transmitted infection (gonorrhea, chlamydia, trichomoniasis) was not associated with increased risk of transmission when examined individually or combined into a single variable. However, bacterial vaginosis was significantly more prevalent among women who transmitted in utero: 59% of transmitters vs. 35% of women who did not transmit had bacterial vaginosis in the cohort (P ¼ 0.02). In addition, transmitting women were more likely to have had an AIDS-defining illness during the past 1 year and a greater proportion of women who transmitted in utero reported an illness prior to 32 weeks of gestation, which was characterized by diarrhea, fever, or cough (41 vs. 21%; P ¼ 0.01 and 52 vs. 28%; P ¼ 0.01, respectively).
These factors were assessed in multivariate analyses adjusting for plasma HIV-1 viral load, CD4 percentage at 32 weeks, and duration of zidovudine use (Table 1 ). Using this model, plasma and cervical HIV-1 RNA levels remained significant predictors of in-utero transmission, conferring a 1.9 and 1.5-fold increase in risk per log 10 change in HIV-1 RNA in plasma and cervical secretions, respectively (P < 0.05 for both). Receipt of zidovudine for at least 3 weeks before delivery also remained protective after adjusting for viral load and disease stage [odds ratio (OR) 0.4; 95% CI 0.2-1.0; P ¼ 0.04]. Other independent predictors of in-utero transmission in this model were illness during pregnancy and bacterial vaginosis. Illness during pregnancy was associated with a 2.6-fold increased risk and bacterial vaginosis with a 3-fold increase in the likelihood of transmission in utero (OR 2.6, 95% CI 1.2-5.8; P ¼ 0.02 and OR 3.0, 95% CI 1.0-7.0; P ¼ 0.01, respectively; Table 1 ).
To our knowledge, neither illness in early pregnancy nor bacterial vaginosis has been reported as a risk factor for transmission in utero. Illness during pregnancy may be contributing to increased transmission by transiently elevating HIV-1 viral load or by causing immune activation and increased CD4 target cells. Women describing fever and other complaints during pregnancy may also be manifesting symptoms of acute HIV-1, characterized by a sharp and transient increase in viral load that could elevate transmission risk substantially. The association between bacterial vaginosis and in-utero transmission may be due to bacterial vaginosis organisms causing upper genital tract infections such as chorioamnionitis, endometritis, and placental compromise. Chronic chorioamnionitis has been associated with increased in-utero transmission and could explain negative results from one large clinical trial designed to treat bacterial vaginosis and prevent motherto-child transmission [6, 7] . As both illness in early pregnancy and bacterial vaginosis are amenable to interventions, these data suggest additional means to target the in-utero period, a period that is likely to increase in its relative significance.
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The authors would like to thank all of the study participants and the dedicated clinic and laboratory staff. A single-nucleotide polymorphism (rs2395029) in the HCP5 gene associated with HLA-BM5701 is correlated with lower HIV-1 viral set point. The two allelic forms of coding region were ectopically expressed in TZM-bl cells for an effect on HIV-1 replication. No significant HIV-1 restriction was observed in the cells with infectivity assays throughout HIV-1 life cycle, suggesting that the association of HCP5 variant with viral control is likely due to HLA-BM5701-related effect or other functional variants in the haplotype or both.
A single-nucleotide polymorphism (SNP), rs2395029 in the HLA complex protein P5 (HCP5) gene, is highly associated with HIV-1 viral load at set point [1] [2] [3] . HCP5, mainly expressed in lymphocytes [4] , is a human endogenous retroviral element (HERV) that has been suggested to control retroviruses [5, 6] . The minor allele, associated with improved viral control, is a coding change (Val112Gly) in the putative polypeptide and is in almost perfect linkage disequilibrium with HLA-B Ã 5701 [1, 2, 7] . The HLA-B Ã 5701 allele has been repeatedly associated with improved viral control, delayed progression to AIDS and has been shown to present HIV-1 epitopes evoking strong CD8 þ T cell responses [8] [9] [10] , suggesting that the observed control associated with the HCP5 SNP is at least partially a reflection of the known controlling effect of HLA-B Ã 5701. Here, we have investigated an independent role of the HCP5 variant against HIV-1 through cellular HIV-1 infectivity assays.
We utilized TZM-bl cells that express high levels of CD4 and of the HIV-1 coreceptors CCR5 and CXCR4, are highly sensitive to infection with diverse isolates of HIV-1, and contain a reporter cassette of the luciferase gene expressed under the control of an HIV-1 long terminal repeat [11] to assess viral infectivity. The cDNA of HCP5 open reading frame containing the major allele (399 bp, GI: 47087196) was isolated from peripheral blood mononuclear cells and subcloned into pcDNA3.1/ mycHisA (Invitrogen, Carlsbad, California, USA) in frame with myc epitope at carboxy terminal. The minor allele was generated with a mutagenesis using the major allele. TZM-bl cells were transiently transfected with the HCP5 plasmids using Lipofectamine 2000 (Invitrogen) and subjected to HIV-1 infection with four different HIV-1 viruses (the T-cell-line-adapted MN strain, the Tier2 BG1168 primary isolate, the Tier1 SF162 primary isolate and the Tier1 SF162 Env pseudovirus). Luciferase activity as a measurement of HIV-1 infectivity was determined after 48 h as described [12] .
TZM-bl cells transiently transfected with HCP5 cDNAs expressed high levels of the exogenous HCP5 transcripts, over 1000-fold increase, compared with control TZM-bl cells measured by quantitative real time-PCR (TaqMan; Applied Biosystems, Foster City, California, USA). The HCP5 peptides were also confirmed by anti-myc immunoblot from the transfected cells. However, none of the HCP5 alleles showed any noticeable change in HIV-1 infectivity though the infectivity varied depending on HIV-1 strains (Fig. 1a ). For each HIV-1 strain, the infectivity was independent from HCP5 allelic expression. This result demonstrates that exogenous HCP5 alleles did not affect HIV-1 infection at early stage.
We also attempted to deplete host HCP5 allele by siRNAs (Dharmacon, Lafayette, Colorado, USA) targeting 3 0 untranslated region of endogenous HCP5 transcripts during the overexpressing. We observed that the siRNAs reduced not only endogenous HCP5 transcript but also HIV-1 infectivity, but this effect is likely due to 'off-target effect' of siRNAs [13] because coexpression of the siRNA resistant-HCP5 cDNA (coding region) did not rescue the phenotype.
To assess the potential role of HCP5 alleles at later stage of HIV infection, we generated stable TZM-bl cells expressing the HCP5 alleles through retroviral transduction using a retroviral vector, pLPCX (Clontech, Mountain View, California, USA) and packaging vectors, pVPack-GP and pVPack-VSV-G (Stratagene, La Jolla, California, USA) according to the manufacturer's instructions. Transduced TZM-bl cells were then selected with 0.5 mg/ml puromycin for 1 week, and the HCP5 expression was verified by a quantitative real time-PCR. To validate our infectivity assay, the rhesus monkey TRIM5a gene, a well known HIV-1 restriction factor [14] , was used as a positive control inhibiting HIV-1 infection. First, we determined whether the high expression of HCP5 alleles affects viral productivity in HIV-1infected cells. Production of virus assessed by p24 ELISA (PerkinElmer, Boston, Massachusetts, USA) in the culture supernatant was dramatically increased at day 9 after infection ( Fig. 1b) . However, the amount of HIV-1 virions from either HCP5 allele-expressing cells was indistinguishable from each other and higher than control TZM-bl cells or GFP-expressing cells (Fig. 1b ). Therefore, the HCP5 alleles did not restrict viral production in our observations. As expected, the positive control cells expressing rhesus TRIM5a displayed a very limited amount of p24 production close to background level, demonstrating the accuracy of our assay system.
The culture supernatants from HIV-1-infected cells at day 6 after infection were added to fresh TZM-bl cells as a newly produced viral stock to assess its de-novo viral infectivity. The infectivity in this second round infection was mainly corresponding to the levels of p24 in the culture media and was not significantly affected by HCP5 alleles (Fig. 1c) . Two other independent experiments of p24 production and second round infection showed similar results. These results indicate that later stage of HIV-1 infection was not influenced by the HCP5 expression. , HCP5 mut; , TRIM5a) (c) Culture supernatants from the infection day 6 were added to fresh TZM-bl cells for a second round of infectivity for 48 h ( , p24; , infectivity). Shown are the results of a representative experiment from three independent experiments.
The in-vitro infectivity results reported in the present study demonstrate that HCP5 does not restrict HIV-1 in early stage or in late stage of infection, at least in our cellular system. Therefore, the results reported here and in other studies [15, 16] strongly argue against a direct antiviral effect of the HCP5 gene, though we do not entirely rule out that different HCP5 alleles could elicit different immune responses against HIV-1-infected cells in vivo. Thus, the strong functional data implicating HLA-B Ã 5701 in HIV-1 control make it likely that the immune response triggered by this HLA class I allele is at least partially responsible for the protection. However, it is important to note that multiple functional variants could be present on the same haplotype. In particular, a common polymorphism (rs9264942) located in the upstream region of the HLA-C gene, 35 kb away from the transcription start site, has been shown to be independently associated with HIV-1 control [1] . HLA-B Ã 5701 allele is almost always found on the HLA-C SNP-containing haplotype: the effect of this HLA-C variant is therefore systematically included in the association signal attributed to HLA-B Ã 5701. Here, we utilized in-vitro HIV-1 infectivity assays to evaluate a host genetic candidate, a HCP5 SNP (rs2395029) against HIV-1, demonstrating that the polymorphism had no influence on cellular HIV-1 infection throughout the HIV-1 life cycle.
